| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025738667 |
| P356 | DOI | 10.1111/J.1523-1755.2004.00802.X |
| P698 | PubMed publication ID | 15253732 |
| P5875 | ResearchGate publication ID | 8455269 |
| P2093 | author name string | Franz Schaefer | |
| Elke Wühl | |||
| ESCAPE Trial Group | |||
| Otto Mehls | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 768-776 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure | |
| P478 | volume | 66 |
| Q80112924 | Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors |
| Q81120614 | Advances in pediatric pharmacology, therapeutics, and toxicology |
| Q38061008 | Alport syndrome--insights from basic and clinical research |
| Q37595448 | Alport syndrome: facts and opinions |
| Q36226045 | Ambulatory blood pressure patterns in children with chronic kidney disease |
| Q37152477 | Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study |
| Q28386914 | Blood lead level and measured glomerular filtration rate in children with chronic kidney disease |
| Q36392732 | CKiD (CKD in children) prospective cohort study: a review of current findings. |
| Q36583392 | Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. |
| Q87393483 | Chapter 6: Blood pressure management in children with CKD ND |
| Q37039020 | Chronic Kidney Disease in Children: An Indian Perspective |
| Q79331371 | Chronic kidney disease in children: state of the art |
| Q36120049 | Chronic kidney disease in children: the global perspective |
| Q36420940 | Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative |
| Q36155395 | Clinical research in pediatric nephrology: state of the art. |
| Q38988030 | Complications of pediatric live-donor kidney transplantation: a single center's experience in Egypt |
| Q34135175 | Congenital Anomalies of Kidney and Urinary Tract |
| Q33395128 | Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy |
| Q38639625 | Effect of renal function on antihypertensive drug safety and efficacy in children |
| Q35673075 | Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways |
| Q37765831 | Evaluating different imaging strategies in children after first febrile urinary tract infection |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q27009545 | Focus on prevention, diagnosis and treatment of hypertension in children and adolescents |
| Q48366696 | Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. |
| Q37682708 | Growth and body composition in very young SGA children. |
| Q34520613 | Health and wealth in children and adolescents with chronic kidney disease (K-CAD study). |
| Q36155260 | How have the past 5 years of research changed clinical practice in paediatric nephrology? |
| Q37593672 | Hypertension in children and adolescents: an approach to management of complex hyper-tension in pediatric patients |
| Q36407313 | Hypertension in children with chronic kidney disease: pathophysiology and management |
| Q61868255 | Inappropriate left ventricular mass in children and young adults with chronic renal insufficiency |
| Q36983279 | Insights from the Chronic Kidney Disease in Children (CKiD) study |
| Q92227120 | International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people |
| Q53793595 | Long-term cardiovascular effects of pre-transplant native kidney nephrectomy in children. |
| Q54320254 | Losartan and enalapril are comparable in reducing proteinuria in children. |
| Q64968653 | Management of Hypertension in CAKUT: Protective Factor for CKD. |
| Q30319678 | Nephrotoxicity as a cause of acute kidney injury in children. |
| Q91719895 | Patient Health Beliefs and Characteristics Predict Longitudinal Antihypertensive Medication Adherence in Adolescents With CKD |
| Q79335145 | Prescription of drugs blocking the renin-angiotensin system in Italian children |
| Q24302641 | Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study |
| Q83989287 | Profiling proteinuria in pediatric patients |
| Q80020642 | Progression of chronic renal failure in children with dysplastic kidneys |
| Q35234337 | Progression of glomerular and tubular disease in pediatrics |
| Q35278515 | Progression of pediatric CKD of nonglomerular origin in the CKiD cohort |
| Q38879216 | Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies |
| Q43290735 | Ramipril in the treatment of proteinuria in children after renal transplantation |
| Q33683988 | Randomized, double-blind, controlled study of losartan in children with proteinuria. |
| Q93609101 | References |
| Q37150737 | Renal tract malformations: perspectives for nephrologists |
| Q34169794 | Risk factors for progression of chronic kidney disease |
| Q37433984 | Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children |
| Q36090578 | Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients |
| Q35210549 | Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients |
| Q49500608 | Steroid-resistant nephrotic syndrome: past and current perspectives |
| Q37021240 | Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management |
| Q45400152 | The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease |
| Q81877802 | The role of calcium antagonists in patients with chronic renal failure |
| Q35614311 | Therapeutic approach to FSGS in children |
| Q38967178 | Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. |
| Q36510669 | Therapeutic strategies to slow chronic kidney disease progression |
| Q36906732 | Treatment of hypertension in children and adolescents |
| Q51804987 | Treatment of primary and secondary hypertension in children. |
| Q37624684 | Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview |
| Q38016527 | Update on the pharmacologic treatment of hypertension in pediatrics |
| Q53562791 | Urinary screening and urinary abnormalities in 3-year-old children in Japan. |
| Q34803138 | Vesicoureteral reflux, reflux nephropathy, and end-stage renal disease |
| Q46639802 | What do we know about chronic renal failure in young adults? II. Adult outcome of pediatric renal disease |
| Q36377396 | What is the optimal first-line agent in children requiring antihypertensive medication? |
Search more.